In provoked VTE with ≥1 enduring risk factor, extending anticoagulation with apixaban reduced symptomatic recurrent VTE at 12 mo

Key Result

Extending anticoagulation with apixaban significantly reduced symptomatic recurrent VTE at 12 months in patients with provoked VTE and enduring risk factors.

Key Points

• To assess whether extending anticoagulation therapy with apixaban can reduce symptomatic recurrent venous thromboembolism (VTE) in individuals with at least one enduring risk factor.
• Evaluated patients with provoked VTE and enduring risk factors.
• Administered apixaban for an extended period post-initial treatment.
• Followed patients for 12 months to observe recurrent VTE rates.
• Extended apixaban therapy led to a significant reduction in symptomatic recurrent VTE compared to standard treatment.
• The rate of recurrent VTE in the apixaban group was considerably lower after 12 months.